Cutting edge Phase 1 study is initiated in cancer patients

We are excited to announce the commencement of a cutting edge Phase 1 study  deploying a live genetically modified virus to treat cancer patients with advanced solid tumours. In addition to trials using oncolytic viruses we also work on other studies translating innovative anti-cancer strategies into clinical trials including (a) novel therapies in which cancer genes are switched off (transcriptional targeting) with the aim of causing cancer-specific cell death, and b) the study of certain gene products as potential tumour associated antigens which can be targeted by cancer vaccines.

Professor Pandha is excited by the prospect of being able to offer patients access to cutting edge treatments via the collaboration between the Surrey Clinical Research Centre and St Luke’s Cancer Centre. He states: “This wonderful collaboration draws on the strengths of St Luke’s and the University to give cancer patients genuinely new treatment options. We have expertise and facilities which are second to none, and intend to become one of the UKs leading centres for cancer gene therapy’.

Trim content

Accessibility | Contacting the University | Privacy | Cookies | Disclaimer | Freedom of Information | Surrey web design

© 2002-2021 University of Surrey, Egerton Road, Guildford, Surrey, GU2 7XP, United Kingdom. +44 (0)1483 300800